Missed this event?

See what Steve Street had to say about this event.

Steve Street discussed the "Large Pharma perspective: What lies ahead for early phase drug development over the next 5 years?" on Day 1 of the conference. Steve Street is Vice President for Research, Head of Pfizer R&D Continuous Improvement at Pfizer.

Click here to read a note from the advisory board

• Clare Nott, Senior Clinical Project Manager
• Daren Austin, Head, Biopharm Clinical Pharmacology & Biometrics, GlaxoSmithKline
• David R. Jones, Expert Pharmaco-Toxicologist, MHRA
• James Dow, Director of Clinical Pharmacology & DMPK, Prosidion
• Mark Egerton, Managing Director, Quotient Bioresearch
• Sally Hughes, Senior Director, Clinical Pharmacology & Clinical Diagnostic Services, Eli Lilly
• Assem S. el Baghdady, Director, AlphaBeta Pharma
• Ian Wilding, President, Ian Wilding Associates

Project management and influencing skills for the early clinical phase professional

Meet the regulators and networking dinner

Using real life data to design and optimise an early phase programme with two example drug molecules

• Biomarkers
• Patients in first in man / first in human studies
• Exploratory trials
• Clincal safety
• Clinical Pharmacology
• Accelerating the journey to proof of concept

Vice President, Senior Director, Director, Heads of Department, Manager:

• Early Clinical Development
• Early Phase Clinical
• Exploratory Development
• Clinical Safety
• Clinical Pharmacology
• Clincal Science
• Translational Science
• Clinical Operations
• Clinical Outsourcing
• Project Management
• Exploratory Medicine